2021 American Society of Hematology Annual Meeting*

Download All
December 11-14, 2021; Atlanta, Georgia
Expert faculty review and share their insights and perspectives on key findings in myeloma presented at the 2021 ASH Annual Meeting.
Shaji K. Kumar, MD
Sagar Lonial, MD

Multiple Myeloma

Slidesets Phase I Study of Cevostamab in Patients With Heavily Pretreated R/R MM: Dosing Schedule, Updated Safety and Efficacy Results
Slidesets Phase I MonumenTAL-1: GPCR5D x CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma
Slidesets Phase I/II Study of BCMA x CD3 Bispecific Antibody REGN5458 in R/R MM: Updated Safety and Efficacy Results
Slidesets Dose-Expansion Results From Phase Ib/IIa CC-220-MM-001 Trial: Iberdomide + Dexamethasone in Relapsed/Refractory MM
Slidesets Phase I/II Study: Belantamab Mafodotin With Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Slidesets Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM
Slidesets GMMG-HD7: Phase III Trial of Isatuximab + VRd vs VRD Alone as Induction Therapy for Newly Diagnosed, ASCT-Eligible Multiple Myeloma
Slidesets Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM
Slidesets CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel in Patients With R/R MM: 2-Yr Update
Slidesets GRIFFIN 2-Yr Maintenance Phase Update: Dara + VRd With Dara-R Maintenance vs VRd With R Maintenance for ASCT-Eligible Patients With Newly Diagnosed MM
Slidesets Preliminary Phase I/II Results of Venetoclax/Dara/Dex vs Bortezomib/Dara/Dex in t(11;14) Relapsed/Refractory Multiple Myeloma
Slidesets MCARH109, a GPCRC5D-Targeted CAR T-Cell Therapy, in Relapsed/Refractory MM: A Phase I First-in-Class Trial
Slidesets Final Survival Analysis of BELLINI: Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Slidesets Updated Results From Phase I/II MajesTEC-1 Study: Teclistamab, a BCMA x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Slidesets BCMA x CD3 Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma: Update of a Phase I First-in-Human Study

Read expert perspectives and clinical insights on the most clinically relevant data for multiple myeloma presented at the Hematology 2021 annual meeting.

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: May 12, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings